Overview

Frequency of Hyperparathyroidism in Postmenopausal Osteoporosis and Its Treatment

Status:
Completed
Trial end date:
2022-02-20
Target enrollment:
Participant gender:
Summary
Recently, an increase in the prevalence of hyperparathyroidism and hypovitaminosis D in postmenopause women has been occurring in Mexico and the world. Chronic exposure to the parathyroid hormone (PTH) is catabolic for the bone, worsening the state of osteoporosis. However, it is unclear whether these conditions could significantly improve bone mineral density (BMD). In the present work, it was shown that the resolution of hyperparathyroidism in postmenopausal women improves osteoporosis.
Phase:
N/A
Details
Lead Sponsor:
Hospital Regional 1o de Octubre
Collaborators:
National Polytechnic Institute, Mexico
Universidad Nacional Autonoma de Mexico
Treatments:
Cholecalciferol